Lucid Diagnostics Inc. (“Lucid”) is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (“GERD”), also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (“EAC”). References in this Form 10-K to “we,” “us” and “our” are to Lucid and, unless the context otherwise requires, its subsidiaries.
Company profile
Ticker
LUCD
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
(Lucid Diagnostics Inc. • LucidDx Labs Inc. • CapNostics LLC ...
IRS number
825488042
LUCD stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
18 Apr 24
10-K
2023 FY
Annual report
25 Mar 24
8-K
Unregistered Sales of Equity Securities
14 Mar 24
S-8
Registration of securities for employees
6 Feb 24
S-8
Registration of securities for employees
6 Feb 24
8-K
Unregistered Sales of Equity Securities
30 Jan 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
28 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
24 Nov 23
8-K
Lucid Diagnostics Provides Business Update and Third Quarter Financial Results
13 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
Transcripts
LUCD
Earnings call transcript
2023 Q4
26 Mar 24
LUCD
Earnings call transcript
2023 Q3
14 Nov 23
LUCD
Earnings call transcript
2023 Q2
15 Aug 23
LUCD
Earnings call transcript
2023 Q1
16 May 23
LUCD
Earnings call transcript
2022 Q4
14 Mar 23
LUCD
Earnings call transcript
2022 Q3
14 Nov 22
LUCD
Earnings call transcript
2022 Q2
16 Aug 22
LUCD
Earnings call transcript
2022 Q1
12 May 22
LUCD
Earnings call transcript
2021 Q4
29 Mar 22
LUCD
Earnings call transcript
2021 Q3
16 Nov 21
Latest ownership filings
4
Debra White
23 Feb 24
4
Ronald M Sparks
23 Feb 24
4
Stanley Lapidus
23 Feb 24
4
James L Cox
23 Feb 24
4
JACQUE J SOKOLOV
23 Feb 24
4
Change in insider ownership
20 Feb 24
SC 13D/A
PAVmed Inc.
20 Feb 24
SC 13G
Ayrton Capital LLC
14 Feb 24
SC 13D/A
PAVmed Inc.
2 Feb 24
4
Change in insider ownership
30 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 24.05 mm | 24.05 mm | 24.05 mm | 24.05 mm | 24.05 mm | 24.05 mm |
Cash burn (monthly) | 2.84 mm | 240.33 k | 4.74 mm | 4.75 mm | 2.93 mm | 2.26 mm |
Cash used (since last report) | 18.94 mm | 1.60 mm | 31.58 mm | 31.65 mm | 19.52 mm | 15.06 mm |
Cash remaining | 5.11 mm | 22.45 mm | -7.53 mm | -7.60 mm | 4.53 mm | 8.99 mm |
Runway (months of cash) | 1.8 | 93.4 | -1.6 | -1.6 | 1.5 | 4.0 |
Institutional ownership, Q2 2023
68.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 17 |
Opened positions | 2 |
Closed positions | 5 |
Increased positions | 4 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 2.65 bn |
Total shares | 33.17 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
PAVM PAVmed | 31.30 mm | $58.22 mm |
Luminus Management | 878.38 k | $1.22 bn |
Vanguard | 319.83 k | $444.57 mm |
Nantahala Capital Management | 199.07 k | $276.71 mm |
Geode Capital Management | 143.47 k | $199.42 mm |
Bridgeway Capital Management | 135.00 k | $187.65 mm |
Citadel Advisors | 62.51 k | $86.89 mm |
Verition Fund Management | 36.17 k | $50.27 mm |
Geneos Wealth Management | 33.85 k | $47.05 mm |
BLK Blackrock | 26.30 k | $36.56 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
26 Jan 24 | PAVmed | Common Stock | Other | Acquire J | No | No | 1.4033 | 3,331,771 | 4.68 mm | 34,634,191 |
26 Sep 23 | Stanley Lapidus | Common stock | Sell | Dispose S | No | Yes | 1.45 | 9,747 | 14.13 k | 101,592 |
26 Sep 23 | Stanley Lapidus | Common stock | Sell | Dispose S | No | Yes | 1.43 | 10,000 | 14.30 k | 111,339 |
26 Sep 23 | Stanley Lapidus | Common stock | Sell | Dispose S | No | Yes | 1.474 | 10,000 | 14.74 k | 121,339 |
25 Sep 23 | Stanley Lapidus | Common stock | Sell | Dispose S | No | Yes | 1.43 | 200 | 286.00 | 131,339 |
21 Sep 23 | Stanley Lapidus | Common stock | Sell | Dispose S | No | Yes | 1.44 | 100 | 144.00 | 131,539 |
20 Sep 23 | Stanley Lapidus | Common stock | Sell | Dispose S | No | Yes | 1.44 | 412 | 593.28 | 131,639 |
20 Sep 23 | Stanley Lapidus | Common stock | Sell | Dispose S | No | Yes | 1.45 | 3,405 | 4.94 k | 132,051 |
31 Jan 23 | Debra White | Employee stock option Common stock | Grant | Acquire A | No | No | 1.31 | 175,000 | 229.25 k | 175,000 |
News
Needham Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target
12 Apr 24
Cantor Fitzgerald Maintains Overweight on Lucid Diagnostics, Lowers Price Target to $3
27 Mar 24
Needham Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target
27 Mar 24
Lucid Diagnostics Q4 EPS $(0.23) Beats $(0.26) Estimate, Sales $1.04M Miss $1.05M Estimate
25 Mar 24
Lucid Diagnostics Provides Business Update; Reports Q4 EsoGuard Revenue Of $1.04M, Up 33% Sequentially
25 Mar 24
Press releases
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
8 Apr 24
PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results
26 Mar 24
Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results
25 Mar 24
Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
21 Mar 24
Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference
20 Mar 24